MLTX COURT ALERT: MoonLake Immunotherapeutics Investors that Lost Money May have been Affected by Fraud -- Contact BFA Law by December 15

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 clinical trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with investors having until December 15, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in MoonLake common stock [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational drug sonelokimab [3]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated a superior clinical response for patients compared to competitors [4]. Group 3: Clinical Trial Results - The VELA Phase 3 trials for sonelokimab reported disappointing results, with VELA-2 failing to meet its primary endpoint, raising concerns about the drug's regulatory approval and commercial viability [5][6]. - Following the announcement of the trial results on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].